comprehensive -WSS

comprehensive

author：knowledge 2025-09-14 21:40:36 - browse：7111

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Close Medicare's dangerous gaps in addiction treatment coverage

WSS

FDA approves RSV monoclonal antibody for infants, toddlers

H5N1 bird flu found in pasteurized milk: what we know

Listen: Wegovy in the brain & pivotal Alzheimer's data

Bird flu in milk supply is likely coming from asymptomatic cows

Getting Alzheimer's drug Leqembi to patients can be a challenge

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Melinda French Gates resigns from Gates Foundation

Walensky prepares to leave CDC — and Congress — behind

Health care needs a new profession: neuroimaging counseling

Novavax promises a turnaround & Lilly roils the obesity market

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

ChatGPT in medicine: STAT answers readers' burning questions

Why does health care cost so much? A reading guide

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Listen: Wegovy in the brain & pivotal Alzheimer's data

focus

Bird flu outbreak in cows is latest avian flu curveball

H5N1 bird flu virus started spreading in cows in Texas in December

Cell therapy fails to slow type 1 diabetes, but safety is established

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Why rehabilitation engineers need to center patients in their research

At Orexo, a ‘turning point’ for everything but digital health

hotspot

knowledge

focus

knowledge